TABLE 2.
Treatment Outcomes in the entire population (N = 160) and according the Nab‐Paclitaxel plus Gemcitabine line of treatment.
| Response | Overall (160) N (%) | Second line (111) N (%) | Third/fourth line (49) N (%) |
|---|---|---|---|
| CR | 0 | 0 | 0 |
| PR | 36 (22.5) | 25 (22.5) | 11 (22.4) |
| ORR | 36 (22.5) | 25 (22.5) | 11 (22.4) |
| SD | 37 (23.1) | 30 (27.0) | 7 (14.3) |
| DCR | 73 (45.6) | 53 (49.5) | 18 (36.7) |
| PD | 87 (54.4) | 56 (50.5) | 31 (63.3) |
| Duration of DC (months) | |||
| Median | 4.7 | 5.3 | 3.95 |
| Range | 0.8–15.5 | 1.0–16.0 | 2.0–11.0 |
|
CA19.9 response Evaluable (N=156) | |||
| Increase | 85 (54.5) | 56 (51.9) | 29 (60.4) |
| Decrease < 50% | 17 (10.9) | 11 (10.2) | 6 (12.5) |
| Decrease ≥ 50% | 54 (34.6) | 41 (38.0) | 13 (27.1) |
Abbreviations: CR, complete response; DC, disease control; DCR, disease control rate; ORR, overall response rate; PD, progression disease; PR, partial response, SD, stable disease.